Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer
Condition(s):Oropharyngeal Cancer; Hypopharyngeal CancerLast Updated:March 20, 2012Unknown status
Hide Studies Not Open or Pending
Condition(s):Oropharyngeal Cancer; Hypopharyngeal CancerLast Updated:March 20, 2012Unknown status
Condition(s):Oropharynx Cancer; Squamous Cell Carcinoma of the Oral CavityLast Updated:May 18, 2016Completed
Condition(s):Oropharynx CancerLast Updated:September 5, 2021Completed
Condition(s):Head and Neck Cancer; Oropharynx Cancer; Human Papilloma VirusLast Updated:December 12, 2023Recruiting
Condition(s):Metastatic Oropharyngeal Carcinoma; Recurrent Oropharyngeal CarcinomaLast Updated:November 18, 2023Recruiting
Condition(s):Head and Neck CancerLast Updated:January 22, 2024Active, not recruiting
Condition(s):Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Oropharyngeal HPV-Positive Squamous Cell CarcinomaLast Updated:August 9, 2023Recruiting
Condition(s):Oropharynx Cancer; Head and Neck Cancer; XerostomiaLast Updated:March 22, 2024Not yet recruiting
Condition(s):Speech IntelligibilityLast Updated:July 24, 2023Recruiting
Condition(s):Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8Last Updated:December 3, 2021Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.